MedTrace Logo

Cannabidiol (CBD) for the Treatment of Alcohol Withdrawal

NCT04205682 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2020-01-09

No results posted yet for this study

Summary

This study will explore the effectiveness and tolerability of Cannabidiol (CBD) in the treatment of alcohol withdrawal symptoms in an inpatient setting, in a double-blind randomised placebo-controlled trial.

Conditions

  • Alcohol Withdrawal
  • Alcohol Dependence

Interventions

DRUG

Cannabidiol

CBD capsules administered BD for 4-days (800-1200 mg/day), placebo day 5

DRUG

Placebo

Placebo capsules administered BD for 5 days

Sponsors & Collaborators

  • University of Sydney

    collaborator OTHER

  • South Eastern Sydney Local Health District

    collaborator OTHER_GOV

  • South West Sydney Local Health District

    lead OTHER

Principal Investigators

  • Paul Haber, MBBS · Sydney Local Health District

  • Nicholas Lintzeris, MBBS · South Eastern Sydney Local Health District

  • Iain McGregor, PhD · University of Sydney

  • Kirsten Morley, PhD · University of Sydney

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-31
Primary Completion
2021-01-31
Completion
2021-01-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04205682 on ClinicalTrials.gov